GO
Loading...

Behind the Merck-Idenix deal

Monday, 9 Jun 2014 | 10:06 AM ET

Merck is buying Idenix Pharmaceuticals for $3.85 billion in a deal that has already been approved by the boards of both companies, reports CNBC's Meg Tirrell.